Pharmaceuticals

Immunotoxin Industry Poised for Rapid Growth, Forecast to Touch $96.77 Billion by 2030 at 7.8% CAGR

February 16, 2026March 11, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the immunotoxin market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Immunotoxin Market expected to grow between 2026 and 2030?

The immunotoxin market has shown substantial growth in recent years. It is projected to expand from $66 billion in 2025 to $71.71 billion in 2026, at a compound annual growth rate (CAGR) of 8.7%. The historical market expansion is attributable to the early success of antibody-toxin conjugates in cancer research, advances in monoclonal antibody engineering, the unmet demand for targeted cancer therapies, the growth of oncology-focused research laboratories, and an improved understanding of tumor-specific antigens.

The immunotoxin market is projected to experience substantial expansion over the upcoming years, with its valuation forecast to reach $96.77 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. Several factors are driving this anticipated growth, including an increasing need for precise oncology therapies, the broadening scope of immunotherapy developments, greater financial commitments to biologics-derived cancer medications, the escalating occurrence of cancers resistant to current treatments, and ongoing advancements in protein engineering techniques. Key trends expected during this period encompass the increased creation of immunotoxins specifically designed for cancer therapy, a stronger emphasis on minimizing unintended toxicity and immune responses, the expanded application of immunotoxins in blood cancers, a broader range of clinical studies involving advanced immunotoxin structures, and sustained investigation into combination immunotoxin treatment approaches.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15828&type=smp

Which Drivers Are Influencing Market Acceleration In The Immunotoxin Market?

The rising prevalence of breast cancer is anticipated to drive the expansion of the immunotoxin market in the future. Breast cancer is characterized as a malignant tumor forming in the cells of the breast, most frequently within the ducts or lobules. The increased occurrence of breast cancer is a result of enhanced screening programs, lifestyle-related risk factors, and longer life expectancy. The immunotoxin market contributes to breast cancer treatment by offering targeted therapies that selectively eradicate cancer cells while minimizing harm to healthy tissue, thereby leading to fewer side effects compared to traditional chemotherapy. For example, in January 2025, the National Breast Cancer Foundation, a US-based organization, stated that one in every eight women in the United States would be diagnosed with breast cancer during her lifetime. In 2024, an estimated 310,720 women and 2,800 men were expected to receive a diagnosis of invasive breast cancer. Thus, the increasing incidence of breast cancer is fueling the growth of the immunotoxin market.

What Segments Are Identified Within The Structure Of The Immunotoxin Market?

The immunotoxin market covered in this report is segmented –

1) By Type: Anthrax Based Toxins, Diphtheria Toxin (DT) And Derivatives, Pseudomonas Exotoxin (PE) And Derivatives, Ribosome Inactivating Proteins Based Immunotoxins, Ribonucleases-Based Immunotoxins, Other Types

2) By Application: Solid Tumors, Leukemias, Other Applications

3) By End User: Hospitals And Clinics, Cancer And Radiation Therapy Centers, Research Labs, Other End-Users

Subsegments:

1) By Anthrax-Based Toxins: Anthrax Lethal Toxin, Anthrax Protective Antigen

2) By Diphtheria Toxin (DT) And Derivatives: Diphtheria Toxin, DT Fragment-Based Immunotoxins

3) By Pseudomonas Exotoxin (PE) And Derivatives: PE38-Based Immunotoxins, PE-Based Fusion Proteins

4) By Ribosome Inactivating Proteins-Based Immunotoxins: Ricin-Based Immunotoxins, Gelonin-Based Immunotoxins

5) By Ribonucleases-Based Immunotoxins: Onconase-Based Immunotoxins, Binase-Based Immunotoxins

6) By Other Types: Shiga Toxin-Based Immunotoxins, Other Toxin-Based Immunotoxins

What Trends Are Projected To Support The Growth Of The Immunotoxin Market?

Companies operating within the immunotoxin market are primarily focused on developing advanced antibody-drug conjugates (ADCs) with the goal of improving the specificity and effectiveness of cancer treatment while simultaneously lessening harm to healthy tissues. ADCs represent targeted biopharmaceutical treatments comprising a monoclonal antibody linked to a cytotoxic drug, facilitating the precise delivery of this toxic payload directly to cancer cells that express a specific antigen, which in turn enhances therapeutic outcomes when compared to conventional chemotherapy. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical company, and Genmab A/S, a Denmark-based biotechnology company, obtained full U.S. FDA approval for TIVDAK, an antibody-drug conjugate specifically designed for patients with metastatic or recurrent cervical cancer. This drug features a monomethyl auristatin E payload engineered to disrupt microtubules and consequently induce cancer-cell death, having shown statistically significant improvements in overall survival, thus establishing it as a promising targeted treatment option for advanced cervical cancer.

Which Key Players Are Driving Competition In The Immunotoxin Market?

Major companies operating in the immunotoxin market are ImmunoGen Inc., Molecular Templates Inc., Mersana Therapeutics, Seagen Inc., MacroGenics Inc., Sutro Biopharma Inc., Celldex Therapeutics, CytImmune Sciences Inc., Pfizer Inc., Roche Holding AG, AbbVie Inc., Bristol Myers Squibb, AstraZeneca plc, Merck KGaA, BioNTech SE, Ipsen Pharma, Innate Pharma Inc., GenScript, Thermo Fisher Scientific Inc., Enzo Life Sciences Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/immunotoxin-global-market-report

Which Region Is Projected To Lead The Immunotoxin Market During The Forecast Period?

North America was the largest region in the immunotoxin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunotoxin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Immunotoxin Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15828&type=smp

Browse Through More Reports Similar to the Global Immunotoxin Market 2026, By The Business Research Company

Immunotoxin Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunotoxin-global-market-report

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795